



Financial Tear Sheet

Corporate Profile

Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, L.L.C. and Cypress Pharmaceuticals, Inc.

Primary IR Contact

Bob Yedid
LifeSci Advisors
Phone: 646-597-6989
Fax: 516-428-8577
E-mail:
Bob@lifesciadvisors.com

Stock Information

PTX.O (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$0.41
Change (%)	▲ 0.01 (0.00%)
Volume	143,620
52 Week Low	\$0.27
Market Cap	\$5,882,121
Rolling EPS	-6.39
PE Ratio	0
Shares Outstanding	14,505,848

Data as of 01/23/19 12:27 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releases & Upcoming Events

November 8, 2018 - 4:01 p.m.
Pernix® Therapeutics Reports Third Quarter 2018
Financial Results

November 2, 2018 - 8:00 a.m.
Pernix Therapeutics to Report Third Quarter 2018
Financial Results on Thursday, November 8

September 12, 2018 - 7:00 a.m.
Pernix Therapeutics Holdings, Inc.'s Subsidiaries
File Notice of Appeal in Patent Litigation
Concerning Zohydro® ER with BeadTek®

There are currently no events scheduled.

SEC Filings

Filing Date	Form
01/10/19	SC 13G/A
01/08/19	4
12/06/18	CT ORDER
11/21/18	8-K

Executive Leadership Team

John Sedor	Chairman of the Board and CEO
Kenneth R. Piña	Senior Vice President, Chief Legal & Compliance Officer and Corporate Secretary
Angus Smith	Senior Vice President, Chief Business Officer and Principal Financial Officer
Christopher J. Bordiuk	Vice President of Human Resources
George P. Jones	Vice President of Sales and Marketing
Anthony M. Orrico	Vice President of Technical and Supply Operations
Glenn Whaley	Vice President of Finance, Principal Accounting Officer and Corporate Controller